Advanced Life Sciences : NDA Submission for Cethromycin in Community Acquired Pneumonia

Oct. 1, 2008 - Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), announced the submission of a new drug application (NDA) for cethromycin in mild-to-moderate community acquired pneumonia (CAP). Advanced Life Sciences also entered into debt and equity financing agreements to strengthen its balance sheet and help fund commitments associated with the NDA submission and pre-commercialization activities.

CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. CAP affects 5.6 million patients in the United States each year, with 10 million physician visits and 2 million hospitalizations occurring annually.

Macrolides and penicillins are currently the front-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance... Advanced Life Sciences' Press Release -

Advanced Life Sciences : Collaboration With UK Ministry of Defence on ALS-886

July 17, 2008 - Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), announced that the United Kingdom's Defence Science and Technology Laboratory ("Dstl") will evaluate the developmental compound ALS-886 as a treatment for chemically induced lung injury. ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in reducing and preventing tissue damage in the lungs. Dstl has experience modeling lung injury and will conduct animal efficacy studies to measure the ability of ALS-886 to improve the clinical outcome following lung injury that results from the inhalation of chemicals that damage the lung surface.
"While we remain focused on our cethromycin partnering and NDA submission activities, we have continued our efforts on the biodefense front. In this regard, we have been pleased to identify additional opportunities to advance our pipeline programs along the way. Thus, we are excited to announce that Dstl has selected ALS-886 for evaluation as a novel therapy with potential to reduce the effects that result from damage to the lung surface... Advanced Life Sciences' Press Release -

Advanced Life Sciences, Cethromycin, Second Pivotal Phase III Trial for Treatment of Pneumonia

Nov. 15, 2007 - Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States... Advanced Life Sciences's Press Release -